Potent estrogen receptor β agonists with inhibitory activity in vitro, fail to suppress xenografts of endocrine-resistant cyclin-dependent kinase 4/6 inhibitor-resistant breast cancer cells

ObjectiveSeventy percent of newly diagnosed breast cancers are estrogen receptor-α positive and HER2/neu negative. First-line treatments incorporate endocrine therapy and cyclin-dependent kinase 4/6 inhibitors. However, therapy resistance occurs in most patients. Hence, there is an urgent need for e...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Lynn M. Marcho, Christopher C. Coss, Menglin Xu, Jharna Datta, Jasmine M. Manouchehri, Mathew A. Cherian
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Frontiers Media S.A. 2025-03-01
Rangatū:	Frontiers in Oncology
Ngā marau:	ER+ breast cancer ERβ CDK4/6 inhibitor-resistant endocrine-resistant breast cancer
Urunga tuihono:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1441896/full
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!